Portage Biotech Announces Participation in January 2022 Investor Conferences

Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) announced its participation in three investor conferences in January 2022, focusing on immuno-oncology therapies. CEO Dr. Ian Walters will join panel discussions at the LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect Conference, along with a fireside chat at the B. Riley Securities’ Oncology Investor Conference. The company, engaged in developing first-in-class cancer therapies, currently has 10 products in development with clinical readouts expected in the next 12-24 months.

Positive

• Participation in multiple investor conferences can enhance visibility and attract potential investors.
• Engagement in panel discussions indicates thought leadership in the immuno-oncology space.

Negative

• None.

WESTPORT, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company will participate in three investor conferences during the month of January.

As part of the Company’s participation, CEO Dr. Ian Walters will join other thought leaders in the oncology space two panel discussions on next-generation immuno-oncology therapies and the future of immuno-oncology at the LifeSci Partners 11^th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference, respectively, and will also join a fireside chat discussion at the B. Riley Securities’ 2022 Oncology Conference.

Registration and other details for each event are as follows:

     11^th Annual LifeSci Partners Corporate Access Event
     Date: January 5-7, 2022
     Format: 1-on-1 investor meetings
     Panel Discussion:
          Next Gen Immune-Oncology Panel
          January 7, 2022 at 7:30am ET 
          Registration - https://lifesci.events/LifeSci2022

     H.C. Wainwright BioConnect Conference
     Date: January 10-13, 2022
     Format: 1-on-1 investor meetings; on demand pre-recorded presentation available through conference portal
     Panel Discussion:
          New Directions in Immuno-Oncology

     B. Riley Securities’ Oncology Investor Conference
     Date: January 27-28, 2022
     Format: Fireside chat January 28, 2022

About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

Forward-Looking Statements

This news release contains statements about the Company’s information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations        

Chuck Padala
chuck@lifesciadvisors.com

Media Relations
Gwen Schanker
gschanker@lifescicomms.com

FAQ

What conferences is Portage Biotech participating in January 2022?

Portage Biotech is participating in the LifeSci Partners Corporate Access Event, H.C. Wainwright BioConnect Conference, and the B. Riley Securities’ Oncology Investor Conference.

Who will represent Portage Biotech at the investor conferences?

CEO Dr. Ian Walters will represent Portage Biotech at the investor conferences.

When is the LifeSci Partners Corporate Access Event?

The LifeSci Partners Corporate Access Event is scheduled for January 5-7, 2022.

What is the focus of Portage Biotech's panel discussions?

The panel discussions will focus on next-generation immuno-oncology therapies and the future of immuno-oncology.

How many products does Portage Biotech currently have in development?

Portage Biotech has 10 products currently in development.